Skip to content
DataLookout
Menu

NCT07902583

Pancoronavirus Vaccine Study in Healthy Adults Ages 18-55

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of participants with solicited local and systemic reactogenicity events from the time of each study vaccination through 14 days after each study vaccination by dosage amount
Timeframe: Up to Day 15, up to Day 43
Number of participants with study product-related and unrelated unsolicited non-serious adverse events from the time of the first study vaccination through approximately 28 days after the last study vaccination (Day 57) by dosage amount
Timeframe: Up to Day 57
Number of participants with clinical safety laboratory adverse events from the time of each study vaccination through approximately 28 days after each study vaccination by dosage amount
Timeframe: Up to Day 29, up to Day 57
Number of participants with AESIs, SAEs, MAAEs, NOCMCs, and PIMMCs at any time following the first vaccination through 12 months following the last dose received by dosage amount
Timeframe: Up to Day 394

Secondary (3)

Geometric mean ID50 titers (IU50/mL) of neutralizing antibody levels against multiple betacoronaviruses before vaccination and 28 days (Day 57) following second vaccination
Geometric mean fold rise (ID50) titers of neutralizing antibody levels against multiple betacoronaviruses from before vaccination to 28 days (Day 57) following second vaccination
Binding titers (BAU/mL) of antibodies to SARS-CoV-2 Spike (WA-1 isolate) protein from plasma specimens before vaccination to 28 days (Day 57) following second vaccination

Arms and interventions

Cohort 1AActive comparator

Cov-RBD-scNP-001 20 mcg

Cohort 1BActive comparator

Cov-RBD-scNP-001 20 mcg + ACU-026-001-1 1 mg

Cohort 2AActive comparator

Cov-RBD-scNP-001 50 mcg

Cohort 2BActive comparator

Cov-RBD-scNP-001 50 mcg + ACU-026-001-1 1 mg

Cohort 3AActive comparator

Cov-RBD-scNP-001 10 mcg

Cohort 3BActive comparator

Cov-RBD-scNP-001 10 mcg + ACU-026-001-1 1 mg

Biologicals: Cov-RBD-scNP-001, ACU-026-001-1